SG2501
/ Sumgen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 18, 2025
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
(clinicaltrials.gov)
- P1 | N=2 | Terminated | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | N=72 ➔ 2 | Recruiting ➔ Terminated; Adjustment of clinical development plan
Enrollment change • Trial termination • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Oncology
February 26, 2024
SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Phase classification: P1a/1b ➔ P1
Phase classification • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Oncology
February 13, 2023
SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
(clinicaltrials.gov)
- P1a/1b | N=72 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Sep 2024 ➔ Apr 2025 | Trial primary completion date: Feb 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD38 • CD8 • IL2 • IL6 • NCAM1
August 04, 2022
SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
(clinicaltrials.gov)
- P1a/1b | N=72 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2022 ➔ Aug 2022
Enrollment open • Trial initiation date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD38 • CD8 • IL2 • IL6 • NCAM1
March 24, 2022
SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.
(clinicaltrials.gov)
- P1a/1b | N=72 | Not yet recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
New P1 trial • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD38 • CD8 • IFNG • IL1B • IL2 • IL6 • NCAM1 • TNFA
1 to 5
Of
5
Go to page
1